News
-
TIF Thal e-Course: Testimonials from Online Learning Thalassaemia Patients
See what patients from various countries across the world who successfully took TIF‘s Thal e-Course, the ultimate self-paced, interactive, online Εducational Course for individuals with thalassaemia and their families, have to say…
Read More » -
TIF and Hemanext® Inc. Announce New Strategic Alliance
TIF, a worldwide organization dedicated to ensuring equal access to quality healthcare for every patient with thalassaemia and other haemoglobin disorders across the world, and Hemanext Inc., a privately held medical…
Read More » -
TIF Launches Online Petition to Promote ”Equitable Access to Safe and Adequate Blood”
A few days before the celebration of the World Blood Donor Day 2020, TIF has launched an online petition, co-signed by the European Blood Alliance (EBA), to promote ”Equitable Access…
Read More » -
FDA Grants Orphan Drug Designation to Mitapivat for Treatment of Thalassaemia
Agios Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s first-in-class pyruvate kinase-R (PKR) activator Mitapivat for the treatment of…
Read More » -
TIF Issues Position Statement in Honour of the World Blood Donor Day 2020
There is one thing that definitely makes us heroes: giving blood. It is a life-saving gesture that any of us in good health should very seriously consider making. Every couple…
Read More » -
JUST LANDED: The ”Prevention of Inherited Diseases – The Example of β-Thalassaemi” Educational Brochure by TIF
Prevention is the only measure that can drastically reduce the incidencies of severe haemoglobin disorders, such as β-thalassaemia. It is also what allowed countries like Greece, Italy and Cyprus to go from…
Read More » -
WORLD BLOOD DONOR DAY 2020: Give blood and make the world a healthier place
On 14 June 2020 WHO and all countries worldwide will celebrate World Blood Donor Day! The campaign theme for this year’s World Blood Donor Day is “Safe blood saves…
Read More » -
”Why I decided to increase awareness about thalassaemia in Singapore”: The story of Jensen Chan
”I was shocked at the huge discrepancy between how common thalassaemia is and how few people actually know about it.” Jensen Chan, a University student from Singapore, explains how his…
Read More » -
FDA Approves New Formulation for Ferriprox (Deferiprone) Twice-a-Day Tablets
Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., today announced that the U.S. Food and Drug Administration (FDA) has approved Ferriprox® (deferiprone) twice-a-day tablets for the treatment…
Read More » -
Accessibility & Affordability of Novel Therapies for Thalassaemia: The Patients’ Perspective
9 patients with thalassaemia, members of TIF’s Patient Advocacy Group for Thalassaemia and Sickle Cell Disease (T-PAG), are discussing with the Thalassaemia International Federation the accessibility and affordability of the…
Read More »